| Testosterone Undecanoate Replacement Therapy in Boys With Pubertal Delay or Confirmed Hypogonadism (NCT05541172) | Hospital de Niños R. Gutierrez de Buenos Aires | 2022-03-01 |
| D-chiroinositol Administration in Hypogonadal Males (NCT04708249) | Lo.Li.Pharma s.r.l | 2021-01-18 |
| Testosterone in Bariatric Patients (NCT03721497) | Esbjerg Hospital - University Hospital of Southern Denmark | 2020-12-17 |
| Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism (NCT02966652) | Neurocrine UK Limited | 2016-11-03 |
| Autonomic Manifestations of Testosterone Deficiency in Men (NCT02715713) | Texas Tech University Health Sciences Center | 2016-03-01 |
| Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism (NCT02081300) | Lipocine Inc. | 2014-02-01 |
| Safety and Efficacy Trial of Testosterone Undecanoate (NCT01765179) | Clarus Therapeutics, Inc. | 2013-01-01 |
| Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men (NCT01699178) | Clarus Therapeutics, Inc. | 2012-08-01 |
| Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism (NCT01446042) | Acerus Pharmaceuticals Corporation | 2011-09-01 |
| Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men (NCT01403116) | Clarus Therapeutics, Inc. | 2011-07-01 |
| Time to Eugonadal Range, Time to Steady State and Drying Time (NCT01228071) | Endo USA Inc., a Keenova Therapeutics Company | 2010-11-01 |
| Pharmacokinetic Study to Determine Time to Steady-state (NCT00911586) | Clarus Therapeutics, Inc. | 2009-07-01 |
| Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation (NCT00924612) | Clarus Therapeutics, Inc. | 2009-07-01 |
| Registry of Hypogonadism in Men (NCT00858650) | Carelon Research | 2009-03-01 |
| 5-Alpha Reductase and Anabolic Effects of Testosterone (NCT00475501) | VA Office of Research and Development | 2007-01-01 |